For these studies, young (8±9 years), middle-aged (14± 17 years) and aged (23±28 years) rhesus monkeys were used as a model of normal aging in humans to investigate changes in dopamine (DA)-containing neurons in senescence. Aged monkeys exhibited signi®cant age-related motoric declines as compared to the young animals. In vivo microdialysis studies showed that basal levels of the DA metabolites, homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were diminished by 44% and 79%, respectively, in the substantia nigra (SN) of aged monkeys. In addition, D-amphetamine-evoked over¯ow of DA in the SN was diminished by 30% in the middle-aged animals and 67% in the aged monkeys. Post-mortem measures of DA and DA metabolites showed signi®cant decreases in DA (20%), DOPAC (47%) and HVA (22%) levels in the putamen and a 25% decline in HVA tissue levels in the SN of the aged monkeys as compared to the young animals. Unbiased stereological cell counting of tyrosine hydroxylase (TH)-immunoreactive neurons in the SN showed a small (15±20%) but signi®cant agerelated decline in TH-positive neurons. In addition, there was a small (15±20%) but signi®cant decline in TH-positive ®ber density and TH-positive cell size. In comparison to the massive loss of DA neurons responsible for the movement dysfunctions seen in Parkinson's disease, pronounced functional changes in DA release in the SN and putamen may signi®-cantly contribute to the motoric dysfunctions characterizing normal aging in rhesus monkeys.
The hallmark of aging in human and non-human primates is slowing of motor movements ± bradykinesia (Bennet et al. 1996; Fozard and Heikkinen 1998; Zhang et al. 2000) . Other frequently observed parkinsonian-like signs include stooped posture, mild to moderate balance impairments, rigidity and hand tremor. One possible explanation for the similarities between age-related motoric declines and Parkinson's disease (PD) is that the movement dysfunctions in both conditions arise from perturbations of the same neuronal circuitry (Hornykiewicz 1963; Mann and Yates 1982; Hornykiewicz and Kish 1987; Kish et al. 1992) . We have begun to test this hypothesis by comparing age-associated declines in the nigrostriatal dopaminergic system in rhesus monkeys to the well-documented degenerative changes seen in PD. While the extensive loss (> 50%) of dopamine (DA)-containing neurons in the pars compacta of the substantia nigra (SN) does not appear to occur in normal aging in either humans or in many animal models of aging (Fearnley and Lees 1991; McGeer et al. 1977; Mann and Yates 1983; Flood and Coleman 1988; Emerich et al. 1993; Irwin et al. 1994; Emborg et al. 1998; Kubis et al. 2000) , there are other signi®cant changes in the nigrostriatal dopamine pathway. In non-human primates, there are clearly dynamic changes in DA release (Gerhardt et al. 1995) , DA transporter markers (Emborg et al. 1998) , numbers of D2 receptors (Morris et al. 1999) and striatal volume (Matochik et al. 2000) , which may account for some of the abnormalities seen in nigrostriatal function in aging (for a review see Stanford et al. 2001) . At present, the contribution of these variables to motoric de®cits in aged primates and humans remains unclear.
The present study focuses on several of these key variables in behaviorally characterized young and aged rhesus monkeys. Aged rhesus monkeys were used as a model system for studies of age-related changes in motoric function and the nigrostriatal DA system in senescence, as they exhibit the hallmark signs of parkinsonism seen in elderly humans (Emborg et al. 1998; Zhang et al. 2000) . First, the motoric capabilities of young and aged rhesus monkeys were assessed. Second, microdialysis was used to characterize basal and stimulus-evoked levels of DA and DA metabolites in the putamen as well as the SN of behaviorally characterized monkeys. Third, tissue levels of DA and DA metabolites were determined from the putamen and SN of young and aged monkeys. Finally, the number, size and morphological characteristics of DA neurons in the SN, using procedures optimized for identi®cation of TH-positive (TH + ) neurons, were investigated.
The results of this study put into question the idea that ageassociated motoric dysfunctions are simply the consequence of DA neuronal loss in senescence. Rather, changes in the function of DA neurons, and speci®cally age-related changes in the release of DA in other brain areas, such as the SN, appear to be more signi®cant in accounting for the motoric de®cits seen during normal aging in non-human primates and thus, by extension, also in humans.
Methods

Animals and animal care
Young (8±9 years, n 4), middle-aged (14±17 years, n 5) and aged (23±28 years, n 4) female rhesus (Macaca mulatta) monkeys weighing 6±10 kg were used in the present study. Monkeys were housed in individual primate cages in the vivarium facilities at the University of Kentucky College of Medicine. Their care was supervised by veterinarians skilled in the health care and maintenance of non-human primates. The vivarium facilities operate under the guidelines set forth by the National Institutes of Health and are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). The monkeys were maintained on a 12-h/12-h light/dark cycle, with food and water available ad libitum. All protocols used for the monkey studies were approved by the Animal Care and Use Committee of the University of Kentucky.
Measures of motoric behavior in young and aged monkeys Animals were videotaped in their home cage twice a week for 3 consecutive hours beginning at 13.00 h. At the beginning of each hour, a technician entered the room and placed a small piece of fruit on a ledge above the cage door to elicit standing and reaching movements. The animal was then videotaped for 10 min with no one in the room. The technician at that point re-entered the room and placed food (grapes, marshmallows or other small food items) in a test panel attached to the cage. The panel was divided into two sections; the animal could only obtain food from the left section by using its left hand and from the right section with the right hand. Hand and arm use in retrieving the food items was taped. The tapes were coded and evaluated by raters blinded to the experimental conditions using a rating scale adapted from the Uni®ed Parkinson's Disease Rating Scale for humans (Zhang et al. 2000) .
In vivo microdialysis
Custom-made CMA 11 microdialysis probes with a membrane length of 3 mm, diameter of 0.24 mm, and molecular weight cut-off of 6000 were used for all experiments (CMA Microdialysis; North Chelmsford, MA, USA). Probes were perfused at a rate of 1.2 lL/min using a computerized multisyringe pump (Harvard Apparatus Model 22; Harvard Apparatus Inc., Holliston, MA, USA). Dialyzing solutions were loaded into 1-mL capacity gas-tight syringes (Hamilton, Reno, NV, USA), and a short length of FEP tubing (CMA Microdialysis) was used to connect the syringe outlet to the inlet of each probe. Three solutions were prepared prior to each experiment: (1) arti®cial cerebrospinal¯uid (aCSF; 145 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 , 1.2 mM CaCl 2 , 2.0 mM NaH 2 PO 4 , and 0.2 mM ascorbic acid); (2) aCSF with high potassium (47.7 mM NaCl, 100 mM KCl, 1 mM MgCl 2 , 1.2 mM CaCl 2 , 2.0 mM NaH 2 PO 4 , and 0.2 mM ascorbic acid); (3) aCSF containing 250 lM D-amphetamine. The pH of all solutions was 7.4. The addition of D-amphetamine to the dialyzing solution was not seen to alter the separation and quantitation of DA and DA metabolites. In vitro calibrations were carried out prior to each experiment to determine acceptable probes by collecting 30 lL samples from probes immersed in standard solutions maintained at 37°C for at least 1 h. All probes had recoveries for DA, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) of at least 10%. However, data were not corrected for probe recovery as uncorrected values may be better correlated to true values (Glick et al. 1994) .
Neurosurgery procedures for microdialysis recordings
Rhesus monkeys were anesthetized with iso¯urane gas (1±3%) following a pre-operative dose of ketamine hydrochloride [10± 30 mg/kg, intramuscular (i.m.)] and atropine (0.04 mg/kg, i.m). Animals were intubated and placed in a stereotaxic apparatus. Surgery was performed under sterile ®eld conditions. Small holes were drilled in the skull over the right putamen and left SN and the dura pierced with a hypodermic needle. Microdialysis probes were inserted into the right putamen and left SN using the MRI-based co-ordinates for each monkey similar to Gerhardt et al. (1995) . Probes were superfused at 1.2 lL/min and samples were collected every 30 min. Following a 120-min application of aCSF to obtain an estimate of basal levels, excess potassium aCSF was applied continuously for 30 min. Ninety minutes after ending the high potassium perfusion, the D-amphetamine solution was applied continuously for 30 min. Experiments were continued for an additional 90 min post-amphetamine. Prior studies support that the 30-min microdialysis fractions involving potassium-and D-amphetamine-induced over¯ow of DA by reverse microdialysis do not produce robust changes in tissue levels of DA (Hebert et al. 1996; Hoffman et al. 1997) . Animals were maintained under 1±3% iso¯urane gas anesthesia during the entire experiment. Following experimentation, gel foam was placed in the burr holes and the remaining skin was sutured over the exposed areas to seal the wound. All animals recovered from the surgery with little or no behavioral de®cits as assessed using measures of home cage activity levels and daily observation. All animals were administered Ambipen 40 000 units/kg, as an antibiotic, every other day for 10 days.
HPLC coupled with electrochemical detection Dialysates were analyzed via high performance liquid chromatography with electrochemical detection (HPLC-EC) as previously described by Hall et al. (1989) . Brie¯y, 15 lL of the collected sample was loaded via a Beckman Model 507 autosampler through a 50-lL loop onto an ESA ODS-Hypersil column (C18; 3 lm, 80´4.6 mm). The column outlet was connected to an analytical cell (ESA Model 5011) with dual coulometric detectors; an oxidation potential of +380 mV was applied to the ®rst detector, and a reduction potential of ) 250 mV was applied to the second detector. Outputs from both detectors were recorded on stripchart recorders. Mobile phase (1.6 mL/min¯ow rate) consisted of a citrate/acetate buffer solution (pH 4.0) containing 0.35 mM 1-octanesulfonic acid, 0.067 M citric acid monohydrate, 0.1 M sodium acetate, 0.13 mM EDTA, with 7% methanol. Quanti®cations of DA, DOPAC and HVA were based on peak heights and retention times relative to known standard concentrations of each compound. The approximate detection limits of the assay, based on a calculation of three times the standard deviation of the noise, were < 1 pg per injection of DA and DOPAC, and approximately 15 pg per injection for HVA.
HPLC-EC studies of the putamen and SN of young, middle-aged and aged monkeys Several days following the microdialysis measurements, 6±10 tissue punches from the left putamen and SN of each monkey were obtained following removal of the brain and chilling on ice as previously described (Gerhardt et al. 1995) . The punches were transferred to storage tubes, weighed, frozen on dry-ice snow and stored at ) 70°C until they could be assayed. Tissue levels of DA, DOPAC and HVA were determined using the method of Hall et al. (1989) .
We have recently determined that we can reliably use either wet weight of primate brain tissue punches or total protein to express tissue levels of DA and DA metabolites as nanogram per gram wet weight or nanogram per milligram protein . Because protein determinations are more time-consuming than the wet weight measures, we expressed the tissue levels of DA and DA metabolites in the tissue punches as nanogram per gram (ng/g) wet weight for the present experiments.
Quantitative morphology: TH + neuron cell number, cell size and ®ber area Several days following the microdialysis measurements, the animals were over-anesthetized and transcardially perfused with ice-cold saline. After removal and bisection of the brain, the left hemisphere was cut into 4-mm-thick coronal sections in an ice-cold brain mold. Tissue punches from the left putamen and SN (6±10 punches per site) were collected into a tube, weighted, frozen on dry-ice and stored at ) 80°C until they could be assayed (see above).
After bisecting the brain, the right hemisphere was immediately post-®xed in 4% paraformaldehyde followed by 30% sucrose in 0.1 M-phosphate buffer (pH 7.4) at 4°C. Serial 40-lm-thick coronal sections were cut on a frozen sliding microtome and stored in a cryoprotectant solution at ) 20°C until processing. A series of brain slices using every twelfth section was stained for tyrosine hydroxylase immunocytochemistry. Free-¯oating sections were incubated with primary anti-TH antibody (1 : 500, Chemicon International, Inc., Temecula, CA, USA) for 3 nights at 4°C and then exposed to biotinylated secondary antibody (1 : 500, Vector Laboratories, Burlingame, CA, USA) for 1 h. Sections were then incubated in the avidin±biotin±peroxidase complex using the Elite ABC Vectastain Kit (Vector Laboratories). TH immunoreactivity was visualized using 3,3¢diaminobenzidine with nickel enhancement.
The SN was de®ned as consisting of all mid brain TH + neurons except those interspersed with oculomotor nerve rootlets. The number and perikaryal size of TH + neurons in the SN were estimated by using an optical fractionator method for unbiased stereological cell counting (West 1993; Harding et al. 1994) . On each section, a 150´150 lm grid was randomly superimposed with a 100´100 lm dissector counting box placed on each ®fth intersection (Bioquant Image Analysis System; R & M Biometrics Inc., Nashville, TN, USA). A 20-lm-deep fraction of the dissector box was determined by a stage encoder attached to the microscope. All TH + neurons with clearly identi®ed nuclei were counted and their perimeter (minus neurites) measured only if they were either completely within the boundaries of the dissector box or crossing the upper or right side of the box within its 20-lm-depth. The estimated total number of TH + neurons in the SN was calculated based on the following formula: N SQ ±´1 /ssf´1/asf´t/h where N is the estimate of the total numbers of cells, SQ ± is the number of counted cells on the sampled sections through the SN, ssf is the section sampling fraction, asf is the area sampling fraction and t/h is the section thickness fraction (West et al. 1991) . TH + ®ber area in the SN was measured on the same sections. The region of the SN was manually outlined and the threshold of the TH + area over the entire SN was carefully determined and maintained during the measurement. The total area of TH + ®bers in the SN was measured on all of the sampled sections from each animal.
Data analysis
All data are expressed as the mean SEM. The behavioral data from the young, middle-aged and aged monkeys were analyzed using a Friedman's test followed by Mann±Whitney U-post-hoc comparisons. Basal extracellular DA and DA metabolite levels were de®ned as the mean of the two values preceding application of excess potassium. Basal levels were analyzed using one-way analysis of variance (ANOVA) with Newman±Keuls post-hoc comparisons among groups. Microdialysis measures of potassium-and D-amphetamine-evoked over¯ow of DA were analyzed using a two-way ANOVA with repeated measures (age as between-factor and time of fraction collection as within-factor) followed by Newman± Keuls post-hoc comparisons. Whole tissue levels of DA and DA metabolites were analyzed using a one-way ANOVA with Newman± Keuls post-hoc comparisons among groups. The TH + immunohistochemical data involving cell numbers and ®ber area were analyzed using linear regression to assess potential correlation with age. In addition, the average TH + cell numbers, TH + ®ber area and TH + cell size in the young, middle-aged and aged groups were analyzed using a one-way ANOVA with Newman±Keuls post-hoc comparisons. Statistical signi®cance was de®ned as p < 0.05.
Drugs and chemicals
The D-amphetamine sulfate was purchased from Sigma Chemical Co. All other chemicals were analytical or HPLC grade, and were purchased from Fisher Scienti®c (Pittsburgh, PA, USA).
Results
Behavioral studies
We have previously documented that the motoric abilities of adult rhesus monkeys decline during aging (Zhang et al. 2000) . For the present study, a previously developed movement dysfunction rating scale was used to rate animals independently by two observers from 2 days of videotaping. The testing sessions included the retrieval of food (e.g. grape or marshmallow) to elicit movement. This rating scale identi®ed bradykinesia, rigidity in the limbs, tremor in the limbs, ®ne-motor performance in the hands, balance and posture. As seen in Fig. 1 , both the middle-aged and aged animals had signi®cantly lower function ratings than the young animals (Friedman test, p < 0.01; *p < 0.05 for young vs. aged and young vs. middle-aged; Mann±Whitney U-test). Most pronounced were the effects of aging on bradykinesia, ®ne-motor performance and rigidity. Thus, as we have more extensively evaluated and reported (Zhang et al. 2000) , rhesus monkeys display age-associated motoric declines.
In vivo microdialysis in young, middle-aged and aged rhesus monkeys The technique of in vivo microdialysis was used to investigate the dynamics of dopamine release in the putamen and SN of the anesthetized rhesus monkey. Basal levels of DA were consistently measured in the microdialysis samples from the putamen and SN of the young, middle-aged and aged monkeys (see Fig. 2 ). As predicted, the levels of DA were highest in the putamen which correlates with the threeto ®ve-fold higher tissue levels of DA that are observed in this brain region . Levels of DOPAC and HVA were also much greater in the putamen as compared to the SN, again consistent with the greater DA innervation of the putamen. However, there were no age-related There was a signi®cant decline in the middle-aged and aged monkeys as compared to the young animals (Mann±Whitney U-tests; *p < 0.05). Fig. 2 Basal extracellular levels of DA, HVA and DOPAC in the putamen (a) and substantia nigra (b) of young, middle-aged and aged rhesus monkeys. (a) Although there was a trend for a reduction in basal levels of all three compounds during aging in the putamen, the decrease did not reach statistical signi®cance (ANOVA). (b) Both DOPAC and HVA levels were signi®cantly lower in the aged group compared to the young animals (*p < 0.05 vs. the young group, ANOVA followed by Newman±Keuls posthoc comparisons). differences in DA, DOPAC and HVA in the putamen (Fig. 2a) , while DOPAC and HVA levels were signi®cantly decreased in the SN of the old monkeys as compared to the young animals (p < 0.05; Fig. 2b ). Thus, DA metabolism was decreased in the SN of the aged monkeys.
Both excess potassium and D-amphetamine stimulation by reverse microdialysis were used to study evoked release of DA in the putamen and SN of the young, middle-aged and aged monkeys. The average DA levels are seen in Fig. 3 . Excess potassium and D-amphetamine stimulation were seen to produce signi®cant (p < 0.05 for both stimuli) increases in the microdialysis levels of DA in the putamen of the anesthetized rhesus monkey (Fig. 3a) . There were small but signi®cant decreases in D-amphetamine-evoked release of DA in the middle-aged and aged monkeys as compared to the young animals. In contrast, signi®cant agerelated decreases in D-amphetamine-evoked DA release were observed in the SN of both middle-aged and aged monkeys as compared to the young animals (*p < 0.05; Fig. 3b ). However, potassium-evoked over¯ow of DA in the SN, while signi®cantly increased versus baseline for all three age groups (p < 0.05 for young, middle-aged and aged monkeys), was not signi®cantly affected in aging. Thus, somewhat analogous to the changes seen in basal levels of HVA and DOPAC, D-amphetamine-evoked release of DA was seen to be signi®cantly lower in the SN of middle-aged and aged rhesus monkeys.
Post-mortem tissue levels of DA and its metabolites Post-mortem whole tissue levels of DA and DA metabolites were also investigated in the SN and putamen of the young, middle-aged and aged monkeys (Fig. 4) . DA, HVA and DOPAC levels in the putamen were modestly but signi®-cantly lower in the aged group compared to the young and middle-aged animals (*p < 0.05, ANOVA followed by Newman±Keuls post-hoc comparisons; Fig. 4a ). By contrast, the only statistically signi®cant difference observed in the SN was a decrease in HVA levels in the aged animals compared to the young and middle-aged monkeys (*p < 0.05, ANOVA followed by Newman±Keuls post-hoc comparisons; Fig. 4b ). Thus, only modest changes in the whole tissue levels of DA and DA metabolites were observed in the putamen and the SN of aged monkeys.
TH immunohistochemical studies of the SN of young and aged monkeys
Unbiased stereological cell counting methods were employed to investigate the numbers of DA neurons in the SN pars compacta (SNc) of young versus aged rhesus monkeys. As seen in Fig. 5(a) , using linear regression analysis, there was a small but statistically signi®cant (p < 0.05) decline in the number of TH + cells in the SNc with increasing age. However, as depicted in the ®gure inset, there was not a signi®cant age effect in cell number if the data were divided into young, middle-aged and aged groups. In the young animals, less than 10 years of age, average numbers of TH + cells in the pars compacta SN in one hemisphere of the animals averaged approximately 230 000 cells. By contrast, animals ³ 20 years of age, averaged approximately 170 000 cells. However, it is noted that one 28-year-old animal Fig. 3 Dialysate levels of DA from the putamen (a) and substantia nigra (b) of young (s), middle-aged (h) and aged (m) rhesus monkeys. Potassium (100 mM) and amphetamine (250 lM) were locally applied as indicated by the bars on the graph to evoke the over¯ow of DA. (a) There was no effect of age in the overall ANOVA for the effects of potassium and D-amphetamine. There was a signi®cant interaction (age´time). Post-hoc analysis indicated that over¯ow of DA was less in the middle-aged and aged animals compared to the young animals at 150 and 180 min (p < 0.05). (b) There was a signi®cant effect of age and a signi®cant interaction (age´time) in the overall ANOVA for D-amphetamine-evoked over¯ow. Post-hoc analyses indicated that D-amphetamine-evoked over¯ow of DA was less in the middle-aged and aged monkeys compared to the young animals at 150 and 180 min, and that evoked over¯ow of DA was less in the aged animals when compared to the middle-aged monkeys at the same two time points (*p < 0.05 vs. young animals, + p < 0.05 vs. middle-aged monkeys; two-way ANOVA followed by Newman±Keuls post-hoc comparisons). Interestingly, potassium stimulation produced a signi®cant increase in DA in all three aged groups (p < 0.05, two-way ANOVA followed by Newman±Keuls post-hoc comparisons). However, there was no signi®cant difference between the three age groups.
showed substantial reductions at the level of about 125 000 neurons. In addition, one 24-year-old animal had levels similar to the young monkeys. Thus, although signi®cant, these data support the hypothesis that there are only modest ( 15±20%) declines in the number of SNc TH + cells in the course of normal aging in rhesus monkeys. as seen in the ®gure inset, there was no effect of age if the data were divided into the young, middle-aged and aged groups (p > 0.05, oneway ANOVA followed by Newman±Keuls multiple comparisons). Note that some of the aged monkeys > 20 years were seen to have a normal compliment of TH + neurons. (b) Average TH + ®ber area vs.
age. There was a signi®cant decline (r 2 0.39; p 0.024) in the average TH + ®ber area as a function of age. However, as seen in the ®gure inset, there was no effect of age if the data were divided into the young, middle-aged and aged groups (p > 0.05, one-way ANOVA followed by Newman±Keuls multiple comparisons). (c) Average size of TH + cell bodies versus age. There was a signi®cant (*p < 0.05; oneway ANOVA followed by Newman±Keuls multiple comparisons) agerelated decline in the size of the TH + cell bodies in the substantia nigra pars compacta of both middle-aged and aged monkeys as compared to the young animals. Fig. 4 Whole tissue levels of DA, HVA and DOPAC in the putamen (a) and the substantia nigra (b) of the three age groups. (A) DA, HVA and DOPAC levels were signi®-cantly lower in the aged group compared to the young and middle-aged animals (*p < 0.05, ANOVA followed by Newman± Keuls post-hoc comparisons). (b) Tissue levels of DA, HVA and DOPAC in the substantia nigra of the three age groups. The only statistically signi®cant difference was a decrease in HVA levels in the aged animals compared to the young and middle-aged monkeys (*p < 0.05, ANOVA followed by Newman±Keuls post-hoc comparisons).
An additional factor that was investigated was the TH + ®ber area in the SN of the young vs. aged monkeys. As is seen in Fig. 5(b) , using linear regression analysis, there was a small (15±20%) but signi®cant (*p < 0.05) decline in the TH + ®ber area in the SN as a function of age. The Fig. 5 inset demonstrates that there was no age effect on TH + ®ber area if the data were grouped into young, middle-aged and aged animals. The TH + ®ber density in animals £ 10 years of age averaged approximately 68 mm 2 , whereas animals in the ³ 20-year-old-age group averaged approximately 58 mm 2 . Thus, while not extreme, the decline of TH + ®ber area in the SN correlated with declines in TH + cell number in the aged animals as compared to young monkeys.
Finally, an additional study was carried out to investigate the size of the TH + cells in the SNc of the young, middleaged and aged monkeys. As seen in Fig. 5(c) , there was again a small but signi®cant decline (*p < 0.05) in cell size in the middle-aged and aged animals as compared to young controls. Thus, the number of TH + cells, the TH ®ber area and the TH + cell size were all modestly but signi®cantly diminished in the aged animals as compared to young controls.
Discussion
In our studies, aged rhesus monkeys display the hallmarks of aging in humans: bradykinesia, postural instability and limb rigidity. These declines in motoric function were correlated with functional changes in the dynamics of DA release in the SN of these animals. As measured by microdialysis, basal levels of DA in the SN and putamen were unchanged in the young animals as compared to aged monkeys, but HVA and DOPAC were signi®cantly lower in the SN of aged monkeys. In addition, D-amphetamine-evoked over¯ow of DA, but not potassium-induced release of DA, was signi®cantly decreased in the SN in the middle-aged and aged animals as compared to the young monkeys. A small but signi®cant decline of D-amphetamine-evoked release of DA was also seen in the putamen of the middle-aged and aged monkeys. TH-immunohistochemical studies using unbiased stereological cell counting methods demonstrated that the aged animals had a small (15±20%) but signi®cant decline in the number of TH + cells in the SNc as compared to young animals. This correlated with a small but signi®cant decline in TH + ®ber density in the SN and a signi®cant decline in the size of TH + neurons in the SNc. Taken together, these data support that the motoric de®cits observed in aged monkeys correlated with a change in the functional dynamics of DA release and regulation in the SNc and the putamen of aged monkeys.
The striking changes to D-amphetamine-evoked release of DA seen in the SN of aged monkeys were not observed for potassium-evoked depolarization of DA. This is similar to the effects of aging on D-amphetamine and not potassiumevoked over¯ow of DA reported in the Fischer 344 rat (Gerhardt and Maloney 1999) . Taken together, these data support the hypothesis that the levels of the dopamine transporter (DAT) and/or its distribution in the dendrites of aged monkeys may have changed in aging (Gerhardt et al. 1995; . Changes in DAT binding have been reported in the putamen and SN of rats and in the striatum of humans (Allard and Marcusson 1989; Volkow et al. 1998) . The decline of D-amphetamine-evoked release of DA in the SN may relate to a lack of availability of DAT in the dendrites of the SN in the aged monkeys and/or a change in levels of DAT in aging. In fact, the changes may represent compensation for changes in somatodendritic release that occur with age. Additional studies are needed to investigate this interesting ®nding.
Several caveats regarding the interpretation of age-related DAergic cell death as it relates to functional de®cits should be considered. While there have been reports of decreased numbers of DA neurons in aged primates, there are quantitative as well as qualitative differences between the physiological substrates of normal age-related motor de®cits and the pathophysiological substrates of Parkinson's disease (e.g. Fearnley and Lees 1991; Kish et al. 1992; Hubble 1998 ). These differences have become recognized as a result of critical analyses of previous data, improvements in histopathological methodology and analysis of the distinct etiologies of the motor de®cits that accompany each of these conditions. Other considerations relate to the methods used to determine age-related loss of DA neurons. Recent studies using unbiased stereological cell-counting methods in regions other than the basal ganglia have cast doubt on the long-held belief that neuronal death is an inevitable consequence of aging (West 1993; West and Gundersen 1990; West et al. 1994 ; see also Morrison and Hof 1997) . Stereological methods have also challenged previous ®nd-ings regarding the inevitability of nigral cell loss with age (Strothjohann et al. 1993; Irwin et al. 1994; Pakkenberg et al. 1995) . Nevertheless, a recent study using stereological methods to determine age-related nigral cell loss reported a 50% reduction of TH immunoreactive neurons in the SN of aged monkeys (Emborg et al. 1998) . Caution should be exercised when interpreting studies in which the number of DA-containing neurons was determined based on the immunoreactivity of cells to TH. Decreases in TH immunoreactivity may overestimate DA neuronal loss as a result of reduced TH levels in residual cells and variations in staining methods (McGeer et al. 1977; Emborg et al. 1998) .
The number of TH + neurons in the SNc of the aged monkeys was seen to be signi®cantly diminished by 15±20% as compared to the young animals. Taken together with prior studies in humans and animals, the data support that there is unlikely a major change in the number of DA-containing neurons in the SNc during normal aging (Emborg et al. 1998; Flood and Coleman 1988; Irwin et al. 1994; Hebert and Gerhardt 1998; Kubis et al. 2000; Stanford et al. 2001) . These data support the hypothesis that functional changes in DA neurons may account in part for motoric de®cits seen in aged animals and humans. Thus, while DA systems are implicated in movement abnormalities in senescence, evidence indicates that cell loss alone does not explain motoric de®cits seen in aged animals and humans in senescence.
Although the importance of striatal DA is well established, DA in the SN may also play a critical role in normal basal ganglia function. The immunocytochemical localization of DA synthesizing enzymes in the SN, coupled with DA release in the SN, support that nigral neurons can store and release DA (Bjorklund and Lindvall 1975; Paden et al. 1976; Cheramy et al. 1981; Heeringa and Abercrombie 1995; Nirenberg et al. 1996; Cragg et al. 1997; Gerhardt 1998, 1999) . However, the somatodendritic release of DA may not be similar to terminal release (Blakely 2001) . Although nigral DA release can be enhanced by potassium application and inhibited by tetrodotoxin, it is not modulated by low calcium or cadmium (Hoffman et al. 1997; Hoffman and Gerhardt 1999) . In addition, a recent study by Falkenburg et al. (2001) and anatomical evidence (Nirenberg et al. 1996) , support the hypothesis that a major component of dopamine release in the SN may occur through reverse transport by DAT. The decreased levels of D-amphetamineevoked release of DA seen in the SN of aged monkeys are keeping with this mechanism of release. D-amphetamineevoked release of DA is largely calcium independent and occurs through reversal of DAT (Giros et al. 1996) . Further studies are needed to investigate this interesting ®nding and to further understand somatodendritic release of DA in the SN.
Numerous prior studies have focused on DA release in the SN of normal and 6-hydroxydopamine-lesioned rodents (Paden et al. 1976; Cheramy et al. 1981; Heeringa and Abercrombie 1995; Cragg et al. 1997; Gerhardt 1998, 1999) . The present studies in the SN support that the effects of D-amphetamine are clearly more robust that than those seen from excess potassium. Interestingly, the whole tissue levels of dopamine are nearly 5±10 times greater in the monkey SN as compared to the rat (Hoffer et al. 1994) . In addition, the extracellular levels of HVA, a major DA metabolite, are over 10-fold higher in the monkey SN as compared to the rat (Hoffman et al. 1997) . Taken together, these data support a robust level of somatodendritic DA signaling in the monkey SN that is greatly altered in the aged animal.
The DA projections to the striatum are classically viewed as the most important pathways for the role of DA in normal motor control. However, it is widely known that the SNc sends processes containing DA ®bers to the internal and external segments of the globus pallidus, the subthalamic nucleus and dendrites into the reticulata of the SN (Smith and Kievel 2000) . Prior studies have shown that somatodendritic release of DA appears to be a normal component of basal ganglia function (Crocker 1997; Bjorklund and Lindvall 1975; Paden et al. 1976; Robertson and Robertson 1989; Timmerman and Abercrombie 1996) . In fact, functional D1 receptors are located on pre-synaptic, GABAergic neurons (Miyazaki and Lacey 1998; Radnikow and Misgeld 1998; Smith and Kieval 2000) . Somatodendritic release of DA in the pars reticulata of the SN appears to directly modulate GABAergic signaling in the thalamus. This would affect the output through the thalamus and the motor cortex. Thus, in the present study, the changes observed in the SN in normal aging, may relate to a change in somatodendritic release of DA in normal aging that may account in part for the motoric de®cits that are seen in aged animals and possibly humans.
These are the ®rst functional studies of DA release that have been carried out in the putamen and SN of young, middle-aged and aged rhesus monkeys. These data support the hypothesis that functional changes occur to the DA neuronal system in aging and these changes are pronounced in the SN. Decreases in the somatodendritic release of DA correlated with decreases in the motor performance of middle-aged and aged monkeys as compared to young animals. The SN may be an important site for the functional changes that occur in the basal ganglia during aging and in Parkinson's disease.
